Tags

Type your tag names separated by a space and hit enter

Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
Biol Psychiatry 2008; 64(10):850-5BP

Abstract

BACKGROUND

Clinical criteria for differentiating Parkinson's disease (PD) with dementia (PDD) from dementia with Lewy bodies (DLB) are unsatisfactory. Their existence as distinct clinicopathologic entities is still debated, although the burden of Alzheimer's disease (AD) pathology seems higher in DLB. Thus, analysis of cerebrospinal fluid (CSF) biomarkers (beta-amyloid(1-42) [Abeta42], total tau, and hyperphosphorylated tau [p-tau]) in living subjects might provide significant pathophysiological information on these diseases.

METHODS

Cerebrospinal fluid biomarkers were measured in DLB (n = 19), PDD (n = 18), and AD (n = 23) subjects matched for age, sex, and dementia severity, as well as in PD (n = 20) and normal control subjects (n = 20).

RESULTS

DLB showed the lowest mean CSF Abeta42 levels, with a negative association to dementia duration (rho = -.42, p = .07). In DLB patients, mean CSF total tau levels were significantly lower than in AD patients (508 +/- 387 vs. 960 +/- 619, respectively) but twofold to threefold higher than in PDD (286 +/- 184), PD (160 +/- 64), or normal control subjects (177 +/- 76), with a positive association to dementia severity (Mini-Mental State Examination: rho = -.54, p = .02; Milan Overall Dementia Assessment: rho = -.66, p = .002). PDD patients had mean CSF Abeta42 and total tau levels similar to those seen in PD patients. Hyperphosphorylated tau was significantly increased in the AD group only.

CONCLUSIONS

Cerebrospinal fluid Abeta42 and total tau have a different behavior in DLB and PDD, being related to duration and severity of dementia in DLB alone. Hyperphosphorylated tau is not significantly altered in these conditions.

Authors+Show Affiliations

Section of Neurology, Department of Medical and Surgical Specialties and Public Health, University of Perugia, Perugia General Hospital, Perugia, Italy. parnetti@unipg.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18395699

Citation

Parnetti, Lucilla, et al. "Cerebrospinal Fluid Biomarkers in Parkinson's Disease With Dementia and Dementia With Lewy Bodies." Biological Psychiatry, vol. 64, no. 10, 2008, pp. 850-5.
Parnetti L, Tiraboschi P, Lanari A, et al. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry. 2008;64(10):850-5.
Parnetti, L., Tiraboschi, P., Lanari, A., Peducci, M., Padiglioni, C., D'Amore, C., ... Calabresi, P. (2008). Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biological Psychiatry, 64(10), pp. 850-5. doi:10.1016/j.biopsych.2008.02.016.
Parnetti L, et al. Cerebrospinal Fluid Biomarkers in Parkinson's Disease With Dementia and Dementia With Lewy Bodies. Biol Psychiatry. 2008 Nov 15;64(10):850-5. PubMed PMID: 18395699.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. AU - Parnetti,Lucilla, AU - Tiraboschi,Pietro, AU - Lanari,Alessia, AU - Peducci,Maria, AU - Padiglioni,Chiara, AU - D'Amore,Cataldo, AU - Pierguidi,Laura, AU - Tambasco,Nicola, AU - Rossi,Aroldo, AU - Calabresi,Paolo, Y1 - 2008/04/08/ PY - 2007/07/12/received PY - 2008/02/25/revised PY - 2008/02/26/accepted PY - 2008/4/9/pubmed PY - 2009/4/9/medline PY - 2008/4/9/entrez SP - 850 EP - 5 JF - Biological psychiatry JO - Biol. Psychiatry VL - 64 IS - 10 N2 - BACKGROUND: Clinical criteria for differentiating Parkinson's disease (PD) with dementia (PDD) from dementia with Lewy bodies (DLB) are unsatisfactory. Their existence as distinct clinicopathologic entities is still debated, although the burden of Alzheimer's disease (AD) pathology seems higher in DLB. Thus, analysis of cerebrospinal fluid (CSF) biomarkers (beta-amyloid(1-42) [Abeta42], total tau, and hyperphosphorylated tau [p-tau]) in living subjects might provide significant pathophysiological information on these diseases. METHODS: Cerebrospinal fluid biomarkers were measured in DLB (n = 19), PDD (n = 18), and AD (n = 23) subjects matched for age, sex, and dementia severity, as well as in PD (n = 20) and normal control subjects (n = 20). RESULTS: DLB showed the lowest mean CSF Abeta42 levels, with a negative association to dementia duration (rho = -.42, p = .07). In DLB patients, mean CSF total tau levels were significantly lower than in AD patients (508 +/- 387 vs. 960 +/- 619, respectively) but twofold to threefold higher than in PDD (286 +/- 184), PD (160 +/- 64), or normal control subjects (177 +/- 76), with a positive association to dementia severity (Mini-Mental State Examination: rho = -.54, p = .02; Milan Overall Dementia Assessment: rho = -.66, p = .002). PDD patients had mean CSF Abeta42 and total tau levels similar to those seen in PD patients. Hyperphosphorylated tau was significantly increased in the AD group only. CONCLUSIONS: Cerebrospinal fluid Abeta42 and total tau have a different behavior in DLB and PDD, being related to duration and severity of dementia in DLB alone. Hyperphosphorylated tau is not significantly altered in these conditions. SN - 1873-2402 UR - https://www.unboundmedicine.com/medline/citation/18395699/Cerebrospinal_fluid_biomarkers_in_Parkinson's_disease_with_dementia_and_dementia_with_Lewy_bodies_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0006-3223(08)00240-0 DB - PRIME DP - Unbound Medicine ER -